Literature DB >> 16101545

Resident kidney cells and their involvement in glomerulonephritis.

Jennifer R Timoshanko1, Peter G Tipping.   

Abstract

Each year, worldwide, there is an increasing number of patients with chronic kidney disease that progress to end-stage renal disease. Glomerulonephritis (GN) is the commonest single cause of end-stage renal failure in the world. GN can be a manifestation of primary renal injury or may be a secondary feature of a systemic disease process, for example Systemic Lupus Erythematosus (SLE) and Anti-Neutrophilic Cytoplasmic Antibody (ANCA) associated vasculitis. Understanding of the immunopathogenesis of GN has advanced considerably over the last 25 years, particularly the immune system's role. The injurious role of infiltrating leukocytes and humoral mediators has been emphasised, however, the contribution of intrinsic renal cells has proved difficult to define. Most evidence for the pro-inflammatory capacity of intrinsic renal cells has been derived from in vitro studies. Although cytokine production by intrinsic renal cells has been demonstrated by immunohistochemistry and in situ hybridisation studies in renal tissue during the development of GN, the functional contribution of this cytokine production to renal injury was unknown. Little was known about direct and specific interactions between different glomerular cell types and infiltrating leukocytes in the pathogenesis of GN. The development of mice with genetic deficiencies of pro-inflammatory mediators and cytokines, and the technique of bone marrow transplantation into irradiated recipients to produce chimeric mice with restricted cytokine expression has allowed in vivo assessment of the functional contribution made by intrinsic renal cells. Studies have demonstrated the significant contribution of intrinsic renal cell derived cytokines (e.g. TNF) in mediating GN, whereas others (IL-1beta) have a relatively minor role.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16101545     DOI: 10.2174/1568010054022132

Source DB:  PubMed          Journal:  Curr Drug Targets Inflamm Allergy        ISSN: 1568-010X


  8 in total

1.  No association of monocyte chemoattractant protein-1 -2518 A/G polymorphism with the risk of primary glomerulonephritis in the Polish population.

Authors:  Magdalena Mostowska; Margarita Lianeri; Andrzej Oko; Adrianna Mostowska; Paweł P Jagodziński
Journal:  Mol Biol Rep       Date:  2011-12-28       Impact factor: 2.316

2.  From the Large Scale Expression Analysis of Lupus Nephritis to Targeted Molecular Medicine.

Authors:  Celine C Berthier; Matthias Kretzler; Anne Davidson
Journal:  J Data Mining Genomics Proteomics       Date:  2012-03-27

Review 3.  Cell adhesion molecules in chemically-induced renal injury.

Authors:  Walter C Prozialeck; Joshua R Edwards
Journal:  Pharmacol Ther       Date:  2007-01-23       Impact factor: 12.310

4.  Inflammatory mediators release in urine from mice injected with Crotalus durissus terrificus venom.

Authors:  A Hernández Cruz; L Barbosa Navarro; R Z Mendonça; V L Petricevich
Journal:  Mediators Inflamm       Date:  2011-11-29       Impact factor: 4.711

Review 5.  Lupus nephritis: current update.

Authors:  Ramesh Saxena; Tina Mahajan; Chandra Mohan
Journal:  Arthritis Res Ther       Date:  2011-09-28       Impact factor: 5.156

6.  Respiratory Syncytial Virus Exacerbates Kidney Damages in IgA Nephropathy Mice via the C5a-C5aR1 Axis Orchestrating Th17 Cell Responses.

Authors:  Xinyue Hu; Juntao Feng; Qiaoling Zhou; Lisha Luo; Ting Meng; Yong Zhong; Wei Tang; Shuanglinzi Deng; Xiaozhao Li
Journal:  Front Cell Infect Microbiol       Date:  2019-05-07       Impact factor: 5.293

7.  Novel targets for immunotherapy in glomerulonephritis.

Authors:  Mary H Foster
Journal:  Biologics       Date:  2008-09

8.  Urine annexin A1 as an index for glomerular injury in patients.

Authors:  Shuk-Man Ka; Pei-Yi Tsai; Tai-Kuang Chao; Shun-Min Yang; Yi-Jen Hung; Jin-Shuen Chen; Hao-Ai Shui; Ann Chen
Journal:  Dis Markers       Date:  2014-01-20       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.